cerebryl 800 mg/1 tableta filmom obložena tableta
viennapharm d.o.o. - пирацетам - filmom obložena tableta - 800 mg/1 tableta - 1 filmom obložena tableta sadrži: 800 mg piracetama
cerebryl 1200 mg/1 tableta filmom obložena tableta
viennapharm d.o.o. - пирацетам - filmom obložena tableta - 1200 mg/1 tableta - 1 filmom obložena tableta sadrži: 1200 mg piracetama
cerebryl 1200 mg/1 tableta filmom obložena tableta
viennapharm d.o.o. - пирацетам - filmom obložena tableta - 1200 mg/1 tableta - 1 filmom obložena tableta sadrži: 1200 mg piracetama
cerebryl 800 mg/1 tableta filmom obložena tableta
viennapharm d.o.o. - пирацетам - filmom obložena tableta - 800 mg/1 tableta - 1 filmom obložena tableta sadrži: 800 mg piracetama
kolbam
retrophin europe ltd - kolesku kiselinu - metabolizam, urođene pogreške - bile i jetrena terapija - Холевая kiselina ФГК indiciran za liječenje prirođenih pogrešaka primarnih žučnih kiselina sinteza, kod djece od jednog mjeseca za kontinuirano doživotno liječenje do punoljetnosti, uključuje sljedeće jedan ферментных grešaka:balzam 27-hidroksilaze (predstavljajući kao церебротендинальный ксантоматоз, СТХ) deficit;2- (ili alfa-) methylacyl-koa racemase (protein amacr) deficit;kolesterol-7-alfa-hidroksilaze (cyp7a1) deficit.
ravicti
immedica pharma ab - glicerol fenilbutirat - poremećaji ciklusa ureje, umrli - drugi gastrointestinalni trakt i metabolizam, lijekovi, - ravicti prikazan na primjenu kao dodatna terapija za liječenje kroničnih bolesnika urea ciklusa poremećaja (ucds), uključujući nedostatke карбамоильную fosfat-sintaze-ja (sp), ornitin carbamoyltransferase (otn), argininosuccinate синтетазы (stražnjicu), argininosuccinate ЛиАЗы (АСЛ), аргиназы sam (aug) i ornitin translocase deficit hyperornithinaemia-hyperammonaemia homocitrullinuria sindrom (ННН), koje se ne može upravljati s hranom proteina ograničenje i/ili aminokiselinskih dodataka u miru. ravicti treba koristiti uz ograničenje proteina i, u nekim slučajevima, prehrambenih dodataka (e. , esencijalne aminokiseline, arginin, citrulin, dodatke bez kalorija bez proteina).
purevax rcp felv
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.
purevax rcpch felv
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.
solven 10 mg filmom obložene tablete
viatris limited, damastown industrial park, mulhuddart, dublin, irska - solifenacinsukcinat - filmom obložena tableta - 10 mg - urbroj: svaka filmom obložena tableta sadrži 10 mg solifenacinsukcinata, što odgovara 7,5 mg solifenacina
solven 5 mg filmom obložene tablete
viatris limited, damastown industrial park, mulhuddart, dublin, irska - solifenacinsukcinat - filmom obložena tableta - 5 mg - urbroj: svaka filmom obložena tableta sadrži 5 mg solifenacinsukcinata, što odgovara 3,8 mg solifenacina